TRAIL is a novel antiviral protein against dengue virus.

TRAIL is a novel antiviral protein against dengue virus. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

TRAIL is a novel antiviral protein against dengue virus. Abstract Text:

Rajas V Warke,Katherine J Martin,Kris Giaya,Sunil K Shaw,Alan L Rothman,Irene Bosch,Rajas V Warke,Katherine J Martin,Kris Giaya,Sunil K Shaw,Alan L Rothman,Irene Bosch,

Dengue fever is an important tropical illness for which there is currently no virus-specific treatment. To shed light on mechanisms involved in the cellular response to dengue virus (DV), we assessed gene expression changes, using Affymetrix GeneChips (HG-U133A), of infected primary human cells and identified changes common to all cells. The common response genes included a set of 23 genes significantly induced upon DV infection of human umbilical vein endothelial cells (HUVECs), dendritic cells (DCs), monocytes, and B cells (analysis of variance, P < 0.05). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), one of the common response genes, was identified as a key link between type I and type II interferon response genes. We found that DV induces TRAIL expression in immune cells and HUVECs at the mRNA and protein levels. The induction of TRAIL expression by DV was found to be dependent on an intact type I interferon signaling pathway. A significant increase in DV RNA accumulation was observed in anti-TRAIL antibody-treated monocytes, B cells, and HUVECs, and, conversely, a decrease in DV RNA was seen in recombinant TRAIL-treated monocytes. Furthermore, recombinant TRAIL inhibited DV titers in DV-infected DCs by an apoptosis-independent mechanism. These data suggest that TRAIL plays an important role in the antiviral response to DV infection and is a candidate for antiviral interventions against DV.

TRAIL is a novel antiviral protein against dengue virus. Publishing Authors By Initials

RV Warke,KJ Martin,K Giaya,SK Shaw,AL Rothman,I Bosch,RV Warke,KJ Martin,K Giaya,SK Shaw,AL Rothman,I Bosch,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

TRAIL is a novel antiviral protein against dengue virus. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of virology

VOLUME: 82

Page Numbers: 555-64

Journal Abbreviation: J. Virol.

ISSN: 1098-5514

DAY: 3

MONTH: 10

YEAR: 2007

TRAIL is a novel antiviral protein against dengue virus. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 113724

TRAIL is a novel antiviral protein against dengue virus. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: TRAIL is a novel antiviral protein against dengue virus. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for TRAIL is a novel antiviral protein against dengue virus.

AFFILIATION: Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, S6-712, 55 Lake Ave. North, Worcester, MA 01655, USA.

Country: United States

AGENCY: United States NIAID

GRANT: U19-AI057319

ACRONYM: AI

MEDLINETA: J Virol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

TRAIL is a novel antiviral protein against dengue virus Related Publications

• Author's Reply.
• Automated tracking of the mitral valve annulus motion in apical echocardiographic images using multidimensional dynamic programming.
• Blood volume studies in postoperative liver death.
• Cell type complexity in the basal metazoan Hydra is maintained by both stem cell based mechanisms and transdifferentiation.
• Discovering innate immunity genes using differential display: a story of RNA helicases.
• Durability, negative impact, and neuropsychological predictors of tic suppression in children with chronic tic disorder.
• Effect of verapamil on tachycardia-induced early cellular electrical remodeling in rabbit atrium.
• Elevated levels of soluble ST2 protein in dengue virus infected patients.
• Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
• Heterozygosity for the classical galactosemia mutation does not affect ovarian reserve and menopausal age.
• High incidence of hypermethioninaemia in a single neonatal intensive care unit detected by a newly introduced neonatal screening programme.
• Independent design and conduct of clinical trials.
• Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment.
• Infant mortality among twins and triplets in rural Bangladesh in 1975-2002.
• Localized shape variations for classifying wall motion in echocardiograms.
• Optimized protocol for the large scale production of HIV pseudovirions by transient transfection of HEK293T cells with linear fully deacylated polyethylenimine.
• Portugal's science plots its future.
• Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
• Signatures of Selection in the Human Olfactory Receptor OR5I1 Gene.
• TRAIL is a novel antiviral protein against dengue virus.
• The evolution of immunity: a low-life perspective.
• Transgenic stem cells in Hydra reveal an early evolutionary origin for key elements controlling self-renewal and differentiation.
• Vascular deterioration in cirrhosis: the big picture.
• [Advances in cervical cancer prevention: HPV vaccines]
• [Development of an oxygen-laughing-gas multipurpose apparatus for obstetrical use.]
• [Function of the public health worker in health education.]
• [Is brown adipose tissue a store of long chain polyunsaturated fatty acids during postnatal developing brain?]
• [Not Available.]
• [Notes on the teaching of hygiene to students of medicine.]
• [Training of sanitation personnel in the field of public health education.]